Everett Harris & Co. CA Lowers Stake in AbbVie Inc. $ABBV

Everett Harris & Co. CA cut its stake in AbbVie Inc. (NYSE:ABBV) by 0.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 517,834 shares of the company’s stock after selling 3,425 shares during the period. AbbVie comprises approximately 1.5% of Everett Harris & Co. CA’s portfolio, making the stock its 15th largest position. Everett Harris & Co. CA’s holdings in AbbVie were worth $119,899,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new stake in AbbVie in the second quarter worth $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $39,000. Finally, Bear Mountain Capital Inc. grew its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Bank of America boosted their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup lowered their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research report on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.37.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie Price Performance

Shares of NYSE ABBV opened at $220.42 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market capitalization of $389.56 billion, a P/E ratio of 166.98, a P/E/G ratio of 0.90 and a beta of 0.36. The company’s 50-day moving average is $224.67 and its 200 day moving average is $218.02.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. Research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.